Oct 24 (Reuters) -

ResMed ( RMD ) beat Wall Street estimates for quarterly

profit on Thursday, driven by strong demand for its devices used

for sleep apnea treatment.

Shares of the company rose about 4% in after-hours

trading.

The San Diego, California-based company posted adjusted

profit of $2.20 per share for the quarter ended September 30,

beating estimates of $2.04 per share.

ResMed ( RMD ) makes continuous and bilateral positive airway

pressure machines for non-invasive treatment of sleep apnea - a

condition in which the airway gets blocked multiple times while

sleeping.

The medical device maker's first quarter revenue for the

fiscal year 2025 rose 11% to $1.22 billion, compared to

analysts' estimates of $1.18 billion, according to data compiled

by LSEG.

The revenue growth was driven by increased demand for its

sleep devices and masks portfolio, the company said.

Some analysts expect significant risk of disruption in

patient demand for ResMed's ( RMD ) sleep apnea products next year, as

the U.S. Food and Drug Administration is likely to approve Eli

Lilly's ( LLY ) weight-loss drug Zepbound for sleep apnea by the

end of 2024. The company, however, had previously shrugged off

such concerns.